The psychedelics space is well on its way to becoming dominant in terms of treating a range of medical conditions similar to the cannabis boom we’ve seen over the last decade or so, and companies in the space are vying for a top spot in the capital markets.<\/p>\n
Psychedelics are known for changing or enhancing sensory perceptions and thought processes while also amplifying spiritual experiences. Utilizing psychedelics to treat mental health-related concerns has risen in prominence for disorders such as anxiety, depression, obsessive-compulsive disorder, and other psychiatric conditions.<\/p>\n
As the prominence of these conditions continues to rise, so too does the psychedelics market. According to a from Data Bridge Market Research, the industry is expected to grow at a compound annual growth rate of 13.1 per cent to US$7.56 billion by 2028.<\/p>\n
Driving this growth will be an increase in anxiety and depression and the a renaissance of utilizing psychedelic drugs to treat the afflictions as they continue to show promise of increased efficacy compared to the currently prescribed medications.<\/p>\n
One of the challenges of commercializing psychedelic medications is that the well-known psychedelic drugs are all in the public domain and cannot be patented.<\/p>\n
Companies like Mindset Pharma Inc. (CSE.MSET, OTCMKTS: MSSTF, Forum) are ramping up efforts to tap into this growing market by developing next generation, patent pending psychedelic drug candidates that are specifically designed to be used as medications.<\/p>\n
The company, which is based out of Toronto, Ontario, is currently advancing its next-generation psychedelic medications and chemical synthesis processes; however, it differs from other psychedelics companies in that it has invented completely new psychedelic drug candidates that have been optimized for increased efficacy and safety and are currently awaiting patent approval,.<\/p>\n
More specifically, the company owns three patent-pending psilocybin-inspired drug families, and a fourth inspired by DMT & 5-MeO-DMT.<\/p>\n
Mindset Pharma recently chose its first lead drug candidate, MSP-1014, is from its Family 1 of novel psychedelic compounds. The drug is now moving into current good manufacturing practice (cGMP) compliant manufacturing and investigational new drug (IND)-enabling studies which are required to be completed before entering clinical trials.<\/p>\n
Advancing MSP-1014<\/p>\n
Mindset Pharma’s Family 1 psilocybin-inspired drug family is gearing up for movement into clinical trials, and selecting its lead candidate MSP-1014 is a step closer in the company’s journey in doing so.<\/p>\n
The company said that the drug candidate has shown superior characteristics in direct comparison to psilocybin and its active metabolite psilocin. The advantages of MSP-1014 include increased safety and efficacy.<\/p>\n
MSP-1014 has the potential to be a safer, more efficacious analog to psilocybin, with reduced potential side effects. Given its chemical profile, we anticipate that MSP-1014 will have the potential to treat mood disorders, including major depressive disorder, substance misuse disorders and end-of-life angst associated with terminal illnesses, including cancer,” James Lanthier, CEO of Mindset, said in a press release.<\/p>\n
Lanthier said the company believes MSP-1014 has what it takes to be a first-in-class psychedelic drug candidate. He added that Mindset Pharma can now continue advancing its position in the development of life-changing innovative psychedelic therapeutics that are safer than first-generation psychedelics.<\/p>\n
Our next-generation psychedelic compounds represent the flourishing evolution of therapeutics to effectively address neurological and neuropsychiatric disorders,” he said.<\/p>\n
Mindset Pharma’s Family 1 compounds<\/p>\n
Mindset’s Family 1 compounds leverage modern drug design practices to create proprietary psychedelic drugs that have the potential to be less toxic and more effective.<\/p>\n
In previous rodent preclinical studies of MSP-1014, the drug candidate showed superior in vivo and safety profiles in mice compared to psilocybin in various doses and 5-HT2A (the serotonin receptor widely believed to be responsible for the psychedelic experience) receptor activation in rats.<\/p>\n
According to the company, the superiority when compared to psilocybin is largely in part due to the incorporation of a conjugated amplification moiety (CAM) which enhances the 5-HT2A specific effects while reducing non-specific effects.<\/p>\n
In addition to the lead candidate, Mindset Pharma’s Family 1 includes several other patent-pending compounds with patent-filing priority dates of February of last year. Mindset has completed a range of specialized in vitro and in vivo tests on its novel compounds to choose the best psychedelic drug candidate to be used in human trials.<\/p>\n
Moving ahead with its other family compounds, Mindset Pharma aims to develop drug candidates from Families 2 to 4 and selecting additional lead candidates down the line.<\/p>\n
The investment Opportunity<\/p>\n
Investors need to keep in mind that because the psychedelics space is still young, it will naturally go through periods of fluctuation just like any other up-and-coming market.<\/p>\n
With that in mind, however, Mindset Pharma is poised to be a game-changer in the next generation of psychedelic medicine thanks to its early dates on patent filings, strong data which indicates efficacy of its 4 drug families and, of course, a broad portfolio full of patent-pending drugs that investors should be watching for down the line.<\/p>\n
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.<\/p>\n
<\/p>\n
Read the original: <\/p>\n
Ready to Tap into the US$7.6 billion Psychedelics Market - Stockhouse<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" The psychedelics space is well on its way to becoming dominant in terms of treating a range of medical conditions similar to the cannabis boom we’ve seen over the last decade or so, and companies in the space are vying for a top spot in the capital markets. Psychedelics are known for changing or enhancing sensory perceptions and thought processes while also amplifying spiritual experiences. Continue reading